Ex Vivo platforms not only can be used to gather additional in vivo model data throughout the in-life portion of an oncology study as well as at study completion, they also can address mechanisms of action for immuno-oncology agents and test for cytotoxicity of oncology therapeutics in an ex vivo system. In this webinar, case studies will be presented to demonstrate physiologically relevant 2D and 3D ex vivo PDX Models.
Register for this webinar to learn:
•How to combine physiologically relevant 2D and 3D ex vivo PDX models with quantitative fluorescence imaging and luminescence assays.
•Why Use Tumor Fragments vs. Other 3D Systems?
•How ex vivo PDX models more accurately reflect tumor heterogeneity and in vivo microenvironment using a tumor fragment approach.
•How incorporating a diversity of readouts, including industry standard CellTiter Glo + fluorescence microscopy, can provide additional insights to drive research programs forward.
•How adapting design flexibility, including drug combinations, treatment length, assay timing (3 days to 21-day assays) and readouts (RNA/Protein isolation) can improve data richness.